3 Stocks I Saw on T...
Celldex Therapeutics Inc. (CLDX: NASDAQ)
$4.08 0.09 | 2.26%
06/04/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -44.80M | -2.53M | -36.52M | -47.50M |
| Operating Gains/Losses | -53.00K | -42.00K | -532.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 154.00K | 220.00K | 1.28M | -1.66M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.08M | -1.19M | -2.46M | 1.22M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -104.00K | -35.66M | 1.38M | 33.80M |
| Other Non-Cash Items | 2.65M | 3.53M | 2.71M | 19.90M |
| Net Cash From Continuing Operations | -35.66M | -30.37M | -29.87M | 18.28M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -35.66M | -30.37M | -29.87M | 18.28M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 460.50K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 51.00M | 42.38M | 2.67M | 0.00 |
| Purchases of Property, Plant & Equipment | -509.00K | -2.10M | -528.00K | -1.30M |
| Acquisitions | 0.00 | 0.00 | 51.65M | 11.00M |
| Purchases of Short-Term Investments | -52.72M | -56.52M | -9.56M | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -1.74K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -2.16M | -16.16M | 45.09M | 10.16M |
| Issuance of Debt | 5.00M | 10.00M | 0.00 | 160.31K |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 36.02M | 1.01M | 668.00K | 10.87M |
| Repayment of Long-Term Debt | -12.50M | -197.00K | -3.13M | -102.39K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -86.00K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 28.43M | 10.82M | -2.46M | 10.93M |
| Effect of Exchange Rate Changes | -9.00K | 2.00K | -12.00K | -13.31K |
| Net Change in Cash & Cash Equivalents | -9.39M | -35.72M | 12.74M | 39.35M |
Portfolios with CLDX
- Portfolio NameUser Type
- Userbio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- User3rdwavemedia Portfolio 1
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- UserSolstock
Latest CLDX Headlines from TheStreet
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- Celldex Targeted Drug Shrinks Breast Cancer 05.23.12 | 04:05 pm
- The Next Big Thing In Biotech: Celldex
05.18.12 | 07:05 am - 7 Stocks Under $10 Making Big Moves 05.17.12 | 12:05 pm
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- Celldex Screw-Up Nixes ASCO Data Slot 05.01.12 | 07:05 am
- Biotech Stock Mailbag: All You Need to Know About Hep C Drugs 04.13.12 | 05:04 am
- 8 Stocks Under $10 Moving Higher 03.20.12 | 12:03 pm
- Biotech Stock Chat: Recap 03.15.12 | 11:03 am
Press Releases for CLDX
- Celldex Therapeutics To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.31.12 | 09:05 am
- Celldex’s CDX-011 Demonstrates High Response Rates In Patients With Metastatic Breast Cancer Expressing Elevated Levels Of GPNMB And In Triple Negative Disease - Business Wire 05.23.12 | 04:05 pm
- Celldex Therapeutics To Host Call To Announce Topline Results From The EMERGE Study In Advanced Breast Cancer - Business Wire 05.18.12 | 10:05 am
- Celldex Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 08:05 am
- Celldex Announces Plans To Release Topline Results From The EMERGE Study In Advanced Breast Cancer - Business Wire 05.01.12 | 07:05 am
- Celldex Announces Exercise Of Over-Allotment Option - Business Wire 03.14.12 | 05:03 pm
- Celldex Reports Fourth Quarter And Fiscal 2011 Financial Results - Business Wire 03.07.12 | 07:03 am
- Celldex Therapeutics To Host Corporate 2011 Year-End And 2012 Objectives Update Call - Business Wire 02.29.12 | 03:02 pm
- Celldex Therapeutics To Present At The Citi 2012 Global Health Care Conference - Business Wire 02.24.12 | 10:02 am
- Celldex Prices Public Offering Of Common Stock - Business Wire 02.24.12 | 09:02 am
Partner Headlines for CLDX
- IsoRay: A Potential Small-Cap Bio-Pharma Multi-Bagger - Seeking Alpha 05.29.12 | 09:05 am
- Pre-Market Most Active for May 24, 2012 : BAC, PPL, EMC, NTAP, HPQ, MTGE, CLDX, TS, FB, MT, QQQ, VOD - NASDAQ 05.24.12 | 12:05 pm
- Analyst Insights: Celldex, InterMune, American Tower, Thermo Fisher, Jiayuan.com May 24th - Wall St. Cheat Sheet 05.24.12 | 11:05 am
- After Hours Most Active for May 23, 2012 : NTAP, HPQ, BAC, BLK, IFSIA, QQQ, F, CLDX, KMI, PFE, ERIC, FB - NASDAQ 05.23.12 | 08:05 pm
- Breast Cancer Immunotherapy: A New Hope In The Fight - Seeking Alpha 03.09.12 | 08:03 am
- Notable Put Options Activity in Celldex Therapeutics - Benzinga 03.06.12 | 01:03 pm
- Notable Put Options Activity in Celldex Therapeutics - Benzinga 02.27.12 | 01:02 pm
- Immunocellular Again Pushing To $2 - Seeking Alpha 02.15.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am





